30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Pasithea Therapeutics Corp (KTTA)

Track

Stock chart
Ticker: KTTA Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
STEINMAN LAWRENCE
1 purchase — total 100,000 USD
Buy 28 Nov 2025
Value US$4,796,794.14 | Price 136.59 | Shares 79,301
Buy 28 Nov 2025
Value US$266,915.91 | Price 233.30 | Shares 90,510
Buy 28 Nov 2025
Value US$24,999.75 | Price 0.75 | Shares 33,333
Proposed sale 12 May 2025
Value US$797.76 | Price 0.83 | Shares 960
Sale 12 May 2025
Value US$792.00 | Price 0.83 | Shares 960
Buy 2 Jun 2023
Value US$12,930.00 | Price 0.43 | Shares 30,000
Buy 17 Oct 2022
Value US$1,110.00 | Price 1.11 | Shares 1,000
Buy 6 Sep 2022
Value US$24,631.78 | Price 1.13 | Shares 21,748
Buy 2 Sep 2022
Value US$13,105.32 | Price 1.14 | Shares 11,507
Buy 1 Sep 2022
Value US$62,629.57 | Price 1.13 | Shares 55,646
Buy 30 Aug 2022
Value US$20,452.28 | Price 1.15 | Shares 17,828
Buy 29 Aug 2022
Value US$5,840.50 | Price 1.17 | Shares 5,000
Buy 19 Aug 2022
Value US$70,938.84 | Price 1.30 | Shares 54,644
Buy 17 Aug 2022
Value US$188,282.83 | Price 1.21 | Shares 155,773
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-12-01 2025-11-28 B Purchase
2.3
STEINMAN LAWRENCE
Non-Executive Director
79,301 -10.6%
136.59
US$4,796,794 		79,301 -10.6% 136.59 US$4,796,794
2025-12-01 2025-11-28 B Purchase
2.3
Marques Tiago

Chief Executive Officer

Executive Director
90,510 +3.1%
233.30
US$266,916 		90,510 +3.1% 233.30 US$266,916
2025-12-01 2025-11-28 B Purchase
Dumesnil Simon
Non-Executive Director
35,375 +29.8%
221.92
US$720,071 		35,375 +29.8% 221.92 US$720,071
2025-05-14 2025-05-12 PrS Proposed sale
2.3
Tiago Reis Marques

Officer, Director

Executive Director
960
0.83
US$798 		960 0.83 US$798
2025-05-14 2025-05-12 S Sale
2.3
Marques Tiago

Chief Executive Officer

Executive Director
960 -2.3%
0.83
US$792 		960 -2.3% 0.83 US$792
2023-06-06 2023-06-02 B Purchase
2.3
STEINMAN LAWRENCE
Non-Executive Director
30,000 +2.3%
0.43
US$12,930 		30,000 +2.3% 0.43 US$12,930
2022-10-19 2022-10-17 B Purchase
0.5
Delaney David

Member of 10% owner group
1,000 +0.4%
1.11
US$1,110 		1,000 +0.4% 1.11 US$1,110
2022-09-06 2022-09-06 B Purchase
1.8
Shahinian Eric

Member of 10% owner group
21,748 +1.3%
1.13
US$24,632 		21,748 +1.3% 1.13 US$24,632
2022-09-06 2022-09-02 B Purchase
1.8
Shahinian Eric

Member of 10% owner group
11,507 +0.7%
1.14
US$13,105 		11,507 +0.7% 1.14 US$13,105
2022-09-06 2022-09-01 B Purchase
1.8
Shahinian Eric

Member of 10% owner group
55,646 +3.4%
1.13
US$62,630 		55,646 +3.4% 1.13 US$62,630
2022-08-31 2022-08-30 B Purchase
1.8
Shahinian Eric

Member of 10% owner group
17,828 +1.1%
1.15
US$20,452 		17,828 +1.1% 1.15 US$20,452
2022-08-31 2022-08-29 B Purchase
1.8
Shahinian Eric

Member of 10% owner group
5,000 +0.3%
1.17
US$5,840 		5,000 +0.3% 1.17 US$5,840
2022-08-26 2022-08-19 B Purchase
0.7
Geller Avi

Member of 10% owner group
54,644 +inf%
1.30
US$70,939 		54,644 +inf% 1.30 US$70,939
2022-08-18 2022-08-17 B Purchase
1.8
Shahinian Eric
155,773 +10.7%
1.21
US$188,283 		155,773 +10.7% 1.21 US$188,283
Explore more

More insider trading research around Pasithea Therapeutics Corp

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America